| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Short Communications |
From the Robert C. Byrd Health Sciences Center, Departments of Pathology and Urology, Program in Genetics and Developmental Biology, West Virginia University, Morgantown, West Virginia
The third isoform (MT-3) of the metallothionein gene family is unique in that it has a limited tissue distribution, is not induced by metals, has a neuronal growth inhibitory activity, and sequesters zinc more effectively under zinc-depleted conditions. The goal of the present study was to determine whether MT-3 was absent in normal breast tissue, was overexpressed in breast cancers, and if MT-3 overexpression would be associated with disease outcome. A combination of immunohistochemistry and reverse-transcription polymerase chain reaction was used to demonstrate that the normal breast had no detectable expression of MT-3 mRNA or protein. Using immunohistochemistry, it was shown that MT-3 was overexpressed in 25 of 34 cases of breast cancer. In all cases of positive staining, MT-3 was diffusely localized to the cytoplasm. The tumors from these 34 cases were divided as to outcome based on known 5-year survival, with 20 patients being disease free at 5 years (good outcome) and the other 14 having recurring disease within 5 years (bad outcome). When analyzed for MT-3 staining, it was shown that there was a trend for increased MT-3 immunoreactivity in the group having bad outcomes. However, when the tumor subgrouping was further defined on the basis of carcinoma in situ (CIS), there was a marked significant difference in MT-3 staining between patients with good and bad outcomes. Limited to DCIS, MT-3 staining was significantly increased in patients with bad outcomes compared to those with good outcomes. Thus, these studies demonstrate that MT-3 is overexpressed in selected breast cancers and that overexpression is associated with tumors having a poor prognosis.
This article has been cited by other articles:
 |
|
 |
|
  I. El Ghazi, B. L. Martin, and I. M. Armitage Metallothionein-3 is a component of a multiprotein complex in the mouse brain. Experimental Biology and Medicine, October 1, 2006; 231(9): 1500 - 1506. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.-H. Bay, R. Jin, J. Huang, and P.-H. Tan Metallothionein as a prognostic biomarker in breast cancer. Experimental Biology and Medicine, October 1, 2006; 231(9): 1516 - 1521. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-Q. Chen, Y.-Y. Cheng, X.-L. Zhao, S.-T. Li, Y. Hou, and Y. Hong Effects of zinc on the induction of metallothionein isoforms in hippocampus in stress rats. Experimental Biology and Medicine, October 1, 2006; 231(9): 1564 - 1568. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. D. Zhou, M. A. Sens, S. H. Garrett, S. Somji, S. Park, V. Gurel, and D. A. Sens Enhanced Expression of Metallothionein Isoform 3 Protein in Tumor Heterotransplants Derived from As+3- and Cd+2-Transformed Human Urothelial Cells Toxicol. Sci., October 1, 2006; 93(2): 322 - 330. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Lee, W. Woo, B. Wu, A. Kummer, H. Duminy, and Z. Xu Zinc Accumulation in N-Methyl-N-Nitrosourea-Induced Rat Mammary Tumors Is Accompanied by an Altered Expression of ZnT-1 and Metallothionein Experimental Biology and Medicine, June 1, 2003; 228(6): 689 - 696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Shimoda, W. E. Achanzar, W. Qu, T. Nagamine, H. Takagi, M. Mori, and M. P. Waalkes Metallothionein Is a Potential Negative Regulator of Apoptosis Toxicol. Sci., June 1, 2003; 73(2): 294 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Genter, D. M. Burman, S. Vijayakumar, C. L. Ebert, and B. J. Aronow Genomic analysis of alachlor-induced oncogenesis in rat olfactory mucosa Physiol Genomics, December 26, 2002; 12(1): 35 - 45. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
